MALCOLM BRENNER to Drug Resistance, Neoplasm
This is a "connection" page, showing publications MALCOLM BRENNER has written about Drug Resistance, Neoplasm.
Connection Strength
0.251
-
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine. Leukemia. 2010 Mar; 24(3):563-72.
Score: 0.063
-
A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle. 2005 Feb; 4(2):203-5.
Score: 0.045
-
A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14228-33.
Score: 0.043
-
Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.
Score: 0.032
-
Applications of gene transfer in hematologic malignancy. Recent Results Cancer Res. 1998; 144:60-9.
Score: 0.027
-
Hematological malignancies. FASEB J. 1997 Jul; 11(8):640-8.
Score: 0.026
-
[Gene therapy of childhood cancers: current status and perspectives]. Bull Cancer. 2003 Mar; 90(3):227-38.
Score: 0.010
-
European School of Oncology position paper. Gene therapy for the medical oncologist. Eur J Cancer. 1995; 31A(9):1531-7.
Score: 0.006